Pragmatic Use of Next-generation Sequencing for Management of Drug-resistant Tuberculosis : Targeted Sequencing to Enhance, Liberate, and Optimize Treatment of Drug-resistant Tuberculosis
TS ELiOT is a stepped-wedge, cluster randomized trial assessing the effect of a next-generation sequencing-based strategy on rifampin-resistant tuberculosis management and patient outcomes..
| Medienart: |
|
|---|
Klinische Studie| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
ClinicalTrials.gov - (2024) vom: 23. Jan. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
610 |
|---|
| Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: September 23, 2022, Last downloaded: ClinicalTrials.gov processed this data on January 31, 2024, Last updated: January 31, 2024 |
|---|
| Study ID: |
NCT05553236 |
|---|---|
| Veröffentlichungen zur Studie: |
|
| fisyears: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
CTG008678774 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CTG008678774 | ||
| 003 | DE-627 | ||
| 005 | 20240131010439.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220928s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)CTG008678774 | ||
| 035 | |a (UBBS_Klinische_Studien)NCT05553236 | ||
| 035 | |a (UBBS_Klinische_Studien)AI153213 | ||
| 035 | |a (UBBS_Klinische_Studien)R01AI153213 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Pragmatic Use of Next-generation Sequencing for Management of Drug-resistant Tuberculosis |b Targeted Sequencing to Enhance, Liberate, and Optimize Treatment of Drug-resistant Tuberculosis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: September 23, 2022, Last downloaded: ClinicalTrials.gov processed this data on January 31, 2024, Last updated: January 31, 2024 | ||
| 520 | |a TS ELiOT is a stepped-wedge, cluster randomized trial assessing the effect of a next-generation sequencing-based strategy on rifampin-resistant tuberculosis management and patient outcomes. | ||
| 650 | 2 | |a Tuberculosis | |
| 650 | 2 | |a Coinfection | |
| 650 | 2 | |a Tuberculosis, Multidrug-Resistant | |
| 650 | 2 | |a HIV Infections | |
| 650 | 4 | |a Study Type: Interventional | |
| 650 | 4 | |a Recruitment Status: Not yet recruiting | |
| 650 | 4 | |a 610 | |
| 773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2024) vom: 23. Jan. |
| 773 | 1 | 8 | |g year:2024 |g day:23 |g month:01 |
| 856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT05553236 |z kostenfrei |3 Volltext |
| 912 | |a GBV_CTG | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 23 |c 01 | ||